PRTA
NASDAQ · Biotechnology
Prothena Corp Plc
$7.97
+0.08 (+1.01%)
Financial Highlights (FY 2026)
Revenue
9.24M
Net Income
-232,792,628
Gross Margin
—
Profit Margin
-2,520.6%
Rev Growth
-43.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 66.9% | 66.9% |
| Operating Margin | -2,216.4% | -1,994.8% | -17.7% | -18.1% |
| Profit Margin | -2,520.6% | -2,394.5% | -16.3% | -12.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.24M | 16.37M | 162.70M | 132.11M |
| Gross Profit | — | — | 108.91M | 88.43M |
| Operating Income | -204,699,781 | -326,474,929 | -28,741,203 | -23,889,033 |
| Net Income | -232,792,628 | -371,280,108 | -26,550,677 | -16,869,914 |
| Gross Margin | — | — | 66.9% | 66.9% |
| Operating Margin | -2,216.4% | -1,994.8% | -17.7% | -18.1% |
| Profit Margin | -2,520.6% | -2,394.5% | -16.3% | -12.8% |
| Rev Growth | -43.6% | -43.6% | +13.5% | +18.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 103.68M | 102.66M |
| Total Equity | — | — | 280.84M | 243.54M |
| D/E Ratio | — | — | 0.37 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -203,848,843 | -343,179,870 | -39,466,979 | -33,822,388 |
| Free Cash Flow | — | — | -19,760,246 | -19,201,664 |